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in	Medicaid	Patients
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Community Health Center Burlington
Mentors: Steven Lidofsky, MD, Charles MacLean, 
MD, Scott Strenio, MD
Problem	
Identification
§ As of 2010, there were 7,200 HCV+ people living in VT (1)
§ The 2014 reported mortality rate in VT for HCV was 5.2 per 
every 100,000 persons (1)
§ Newly reported cases of HCV in VT have been increasing 
as a result of the heroin epidemic (2)
§ HCV is a leading cause of cirrhosis, HCC, and liver 
transplant (3) 
§ With new, safer drug regimens, increased management of 
HCV by primary care providers makes sense.  However, 
majority of patients still managed by specialists.
§ Since there is provider interest in treating HCV at CHCB, 
how can we implement a model to treat HCV there?
§ Policy change in Dec 2016 increased coverage to Medicaid 
patients with fibrosis scores of F2 or higher; requirement 
for 6 mos drug & alcohol abstinence also removed  (4) 
Public	Health	
Cost
§ In 2014 the total cost associated with chronic HCV was 
estimated at $6.5 billion and estimated to peak in 2024 
at $9 billion (3)
§ Lifetime cost of an individual infected with HCV 
estimated at $64,490 (3)
§ 2010-2011 Hospitalization rates for HCV related 
problems increased 190% from 2004-2011 at an 
estimated total cost of $3.5 billion (5)
Community	
Perspective
Charlie	MacLean,	MD
Professor	of	Medicine,	General	Internal	
Medicine	&	Geriatrics
Department	of	Medicine
Associate	Dean	for	Primary	Care
§ What are some existing models for treatment of HCV in primary care settings and how 
successful have those been? The ECHO program in New Mexico started about 20 years ago. 
Essentially, primary care physicians in rural areas were trained by specialists to manage Hep C – all 
they needed were some computers and webcams. One of the benefits to this is that once a week, all 
the providers conference and present their patients. That gives you the benefit of seeing consults on 
maybe 50-100 patients per week rather than just your own. This model was next adopted to WAMI 
states, and now there are over 1,000 hubs across the US. It has expanded to treat multiple diseases, 
including chronic pain and opiate addiction treatment. ECHO’s goal is to be reaching 1 billion 
patients by the year 2020. In Vermont, no matter where you live you’re never more than an hour and 
fifteen minutes from a major hospital, so there’s less of a travel barrier for seeing a specialist. The 
reverse of this model, which has also been successful, is to send a specialist out into a rural area 1 
day a week. So you could send a gastroenterologist out to an underserved community for one clinic 
each week and schedule HCV patients then.
§ What barriers would you anticipate to setting up a treatment protocol for HCV in primary care 
settings, and how might those barriers be overcome? If I wanted to start treating HCV patients at 
CHBC tomorrow, my guess is that the greatest pushback would be from insurance or other 
administrative barriers. The other question is, are there enough cases to stay up on the literature? 
There are a couple of ways to address this. One is to have a close linkage to an expert (ie: a 
gastroenterologist at UVM) who would be attending the major research meetings and keeping up 
with trends in the field, and communicating that knowledge to primary care providers. Another is to 
have HCV treatment be a niche area for one provider in the practice, and that person would keep up 
with developments in the field and serve as a resource for the practice. 
§ How could the success of a program like this be measured? You could create a patient registry 
to collect data on treatment response, adverse effects, adherence to protocol, and monitoring, and 
then compare that to metrics on patients at a medical center like UVMMC.
§ Do you have any suggestions in terms of prioritizing patients who haven’t yet been 
screened?Looking back over the years, I’ve found that screening yield has decreased when testing 
patients who always had normal LFTs. Looking at those trends can be a way to prioritize testing. 
Community	
Perspective
Steven	Lidofsky,	MD	
Director	of	Hepatology,	UVM
§ There were some discrepancies in guidelines I reviewed regarding when to 
order bi-annual ultrasounds to look for HCC versus an annual Fibroscan. sDo
you recommend ultrasounds at that interval for all patients being treated for 
HCV, or only if there is a specific indication for it? HCC surveillance is generally 
reserved for individual with known cirrhosis. Transient elastography is not a tool for 
HCC evaluation, but it is used to evaluate the extent of hepatic fibrosis. There is no 
consensus about its use in any surveillance program.
§ If our goal is to treat patients in-house at CHBC, how much and in what capacity 
do you think GI would need to be involved? HCV treatment eligibility is determined 
by health plans, and the landscape is shifting. I know that VT Medicaid demands HCV 
management by subspecalists currently and restricts medication access based upon 
hepatic fibrosis stage. This may all disappear within the next few years.
§ What thoughts do you have regarding invovlement of gastroenterologists in 
primary care HCV treatment, and about having a provider here “subspecialize” 
to a degree in HCV? The best reason to consider GI evaluation is to exclude the 
presence of cirrhosis (since this requires specific management and beyond HCV 
treatment). About 20-25% of patients with chronic HCV have cirrhosis, and the 
question is how best to screen. One strategy is to send all HCV patients to GI for initial 
evaluation prior to HCV treatment, and another is to use tools like the FIB-4 score to 
avoid sending GI referrals when the probability of advanced hepatic fibrosis is low. 
Having a knowledgeable in house HCV “expert” would be a plus to ensure high 
quality HCV treatment.
Community	
Perspective
Scott	Strenio,	MD
CMO,	Medicaid	VT
§ What are the current DHVA pharmacy guidelines for 
HCV treatment? All patients require a prior authorization 
for treatment, which is available online and spells out all 
the different treatment regimens. In terms of the steps for 
primary care, all you need is one consultation with a 
specialist (either ID or GI) and evidence of fibrosis grade 2 
or 3 – that can be established by any of the listed means, 
including a Fibrosure. A Fibroscan is not necessary for 
every patient.
§ How would you suggest primary care providers 
collaborate with specialists to treat Medicaid patients? 
I would recommend finding a specialist who is interested 
in working with the clinic and supporting treatment in 
primary care. A pharmacist is also a good resource.
§ Can you foresee any potential barriers to treating 
CHCB patients? The medications are delivered, so if a 
patient doesn’t have stable housing that could be a barrier.
Intervention	&	
Methodology
§ 1 – Spoke with providers at CHCB to assess interest and 
feasibility of treating HCV patients there, and to identify 
barriers to doing so
§ 2 – Reviewed AASLD HCV treatment guidelines and 
guidelines presented to CHCB providers by local 
gastroenterologists, and identified discrepancies
§ 3 – Clarified discrepancies in treatment guidelines and 
questions regarding Medicaid coverage with UVM 
physicians and CMO of Medicaid Vermont
§ 4 – Created a treatment algorithm for providers at 
CHCB to determine when and how to treat Medicaid 
patients with HCV.
Results
§ Learned that HCV treatment via primary care for VT 
Medicaid patients is very feasible with current guidelines
§ Created treatment algorithm and resource sheet for CHCB 
providers & presented at weekly provider meeting
Evaluation
§ The effectiveness of HCV treatment for Medicaid 
patients through primary care could be evaluated by 
establishing a patient panel at CHCB and tracking the 
lab monitoring, medication adherence, treatment 
response, and other pertinent variables. This could be 
compared to similar data collected at UVMMC or other 
centers where specialists treat HCV.
§ This algorithm can also be evaluated through 
qualitative feedback from the providers utilizing it.
§ Limitations include time restriction that did not allow for 
as much input from specialists in the development of 
the algorithm as would be ideal, however it can be 
updated in the future. It may also be that many patients 
eligible for treatment are already being followed by 
specialists and therefore are likely to be managed by 
them.
Future	
Recommendations
§ In order to implement the use of the HCV treatment 
algorithm, CHCB will need to identify specialists interested 
in collaboratively managing patients with primary care.
§ Collaborating specialists can serve as a resource for 
CHCB, regularly updating providers on new literature, 
national meetings, etc.
§ One or more providers at CHCB may also choose to adopt 
HCV treatment as a niche area, and also stay abreast of 
updates in the field to serve as an educational resource to 
the practice.
§ Invite Dr. Scott Strenio of Medicaid for a meeting at CHCB 
for any further clarification needed re: Medicaid 
regulations, and to collaborate further on ideas for 
expanding HCV treatment.
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Interview	
Consent	Form
§ Thank you for agreeing to be interviewed. This project 
is a requirement for the Family Medicine clerkship. It 
will be stored on the Dana Library ScholarWorks
website. Your name will be attached to your interview 
and you may be cited directly or indirectly in 
subsequent unpublished or published work. The 
interviewer affirms that he/she has explained the 
nature and purpose of this project. The interviewee 
affirms that he/she has consented to this interview. 
§ Yes __X__ / No _____ If not consenting as above: please 
add the interviewee names here for the department of 
Family Medicine information only.
